Ergoteles’s Burning Rock Biotech BNR Stock Holding History

Ergoteles’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,994	Closed	-$112K	–	1284
2022 Q4	$112K	Sell	4,994 -2,746	-35%	-$62.6K	﹤0.01%	1201
2022 Q3	$185K	Buy	+7,740	New	+$250K	0.01%	1213
2022 Q2	–	Sell	-5,232	Closed	-$486K	–	1649
2022 Q1	$486K	Sell	5,232 -5,490	-51%	-$477K	0.02%	667
2021 Q4	$1.02M	Buy	+10,722	New	+$1.47M	0.04%	414

Other funds holding BNR

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ergoteles's BNR Position: Q1 2023 in Review

Ergoteles sold out of Burning Rock Biotech (BNR) in Q1 2023, closing a stake of 4,994 shares — an estimated $112K sold.

Ergoteles first reported a position in BNR in Q4 2021 and held it in 4 quarters. The position peaked at $1.02M in Q4 2021. 34 funds tracked by Wall St. Rank hold BNR as of Q1 2023.

Ergoteles reported no remaining Burning Rock Biotech position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 4,994 Burning Rock Biotech shares in Q1 2023, an estimated $112K.
Ergoteles first reported a position in Burning Rock Biotech in Q4 2021 and held it in 4 quarters.
Ergoteles's Burning Rock Biotech position peaked at $1.02M in Q4 2021.
34 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.